Enveric Biosciences (ENVB) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives. The patented compounds were designed through Enveric’s proprietary discovery platform and represent an approach to non-hallucinogenic psychedelic-inspired therapeutics. The compounds demonstrated low hallucinogenic liability in preclinical testing, including minimal Head Twitch Response and reduced 5-HT2A receptor activation – two established indicators of hallucinogenic activity in rodents.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Psychedelic: atai, Beckly Psytech to combine in all-share transaction
- Enveric Biosciences Holds 2025 Annual Stockholders Meeting
- Enveric gets U.S. patent for sleep, CNS therapeutics
- Enveric Biosciences announces results from EB-003 trial
- Psychedelic: atai Life Sciences reports Phase 2a study data on BPL-003
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue